277 related articles for article (PubMed ID: 24941345)
1. Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia.
Ostyn B; Hasker E; Dorlo TP; Rijal S; Sundar S; Dujardin JC; Boelaert M
PLoS One; 2014; 9(6):e100220. PubMed ID: 24941345
[TBL] [Abstract][Full Text] [Related]
2. Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance.
Rijal S; Ostyn B; Uranw S; Rai K; Bhattarai NR; Dorlo TP; Beijnen JH; Vanaerschot M; Decuypere S; Dhakal SS; Das ML; Karki P; Singh R; Boelaert M; Dujardin JC
Clin Infect Dis; 2013 Jun; 56(11):1530-8. PubMed ID: 23425958
[TBL] [Abstract][Full Text] [Related]
3. Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain.
Rai K; Cuypers B; Bhattarai NR; Uranw S; Berg M; Ostyn B; Dujardin JC; Rijal S; Vanaerschot M
mBio; 2013 Oct; 4(5):e00611-13. PubMed ID: 24105765
[TBL] [Abstract][Full Text] [Related]
4. Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India.
Srivastava S; Mishra J; Gupta AK; Singh A; Shankar P; Singh S
Parasit Vectors; 2017 Jan; 10(1):49. PubMed ID: 28137296
[TBL] [Abstract][Full Text] [Related]
5. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.
Bhandari V; Kulshrestha A; Deep DK; Stark O; Prajapati VK; Ramesh V; Sundar S; Schonian G; Dujardin JC; Salotra P
PLoS Negl Trop Dis; 2012; 6(5):e1657. PubMed ID: 22629478
[TBL] [Abstract][Full Text] [Related]
6. Pharmacovigilance of Miltefosine in Treatment of Visceral Leishmaniasis in Endemic Areas of Bihar, India.
Pandey K; Ravidas V; Siddiqui NA; Sinha SK; Verma RB; Singh TP; Dhariwal AC; Das Gupta RK; Das P
Am J Trop Med Hyg; 2016 Nov; 95(5):1100-1105. PubMed ID: 27645786
[TBL] [Abstract][Full Text] [Related]
7. Combination Therapy Against Indian Visceral Leishmaniasis with Liposomal Amphotericin B (Fungisome
Goswami RP; Rahman M; Das S; Tripathi SK; Goswami RP
Am J Trop Med Hyg; 2020 Jul; 103(1):308-314. PubMed ID: 32394874
[TBL] [Abstract][Full Text] [Related]
8. Lack of correlation between the promastigote back-transformation assay and miltefosine treatment outcome.
Hendrickx S; Eberhardt E; Mondelaers A; Rijal S; Bhattarai NR; Dujardin JC; Delputte P; Cos P; Maes L
J Antimicrob Chemother; 2015 Nov; 70(11):3023-6. PubMed ID: 26253089
[TBL] [Abstract][Full Text] [Related]
9. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
[TBL] [Abstract][Full Text] [Related]
10. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
[TBL] [Abstract][Full Text] [Related]
11. Adherence to miltefosine treatment for visceral leishmaniasis under routine conditions in Nepal.
Uranw S; Ostyn B; Dorlo TP; Hasker E; Dujardin B; Dujardin JC; Rijal S; Boelaert M
Trop Med Int Health; 2013 Feb; 18(2):179-87. PubMed ID: 23199340
[TBL] [Abstract][Full Text] [Related]
12. Relapse of visceral leishmaniasis after miltefosine treatment in a Nepalese patient.
Pandey BD; Pandey K; Kaneko O; Yanagi T; Hirayama K
Am J Trop Med Hyg; 2009 Apr; 80(4):580-2. PubMed ID: 19346379
[TBL] [Abstract][Full Text] [Related]
13. Elimination of Kala-Azar from the Southeast Asia Region.
Bhattacharya SK; Dash AP
Am J Trop Med Hyg; 2017 Apr; 96(4):802-804. PubMed ID: 28115678
[TBL] [Abstract][Full Text] [Related]
14. A Leishmania infantum genetic marker associated with miltefosine treatment failure for visceral leishmaniasis.
Carnielli JBT; Crouch K; Forrester S; Silva VC; Carvalho SFG; Damasceno JD; Brown E; Dickens NJ; Costa DL; Costa CHN; Dietze R; Jeffares DC; Mottram JC
EBioMedicine; 2018 Oct; 36():83-91. PubMed ID: 30268832
[TBL] [Abstract][Full Text] [Related]
15. Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis.
Ramesh V; Dixit KK; Sharma N; Singh R; Salotra P
J Infect Dis; 2020 Feb; 221(4):608-617. PubMed ID: 31854451
[TBL] [Abstract][Full Text] [Related]
16. Oral miltefosine for Indian visceral leishmaniasis.
Sundar S; Jha TK; Thakur CP; Engel J; Sindermann H; Fischer C; Junge K; Bryceson A; Berman J
N Engl J Med; 2002 Nov; 347(22):1739-46. PubMed ID: 12456849
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of oral miltefosine in visceral leishmaniasis in rural West Bengal, India.
Patra P; Guha SK; Maji AK; Saha P; Ganguly S; Chakraborty A; Kundu PK; Sarker S; Ray K
Indian J Pharmacol; 2012; 44(4):500-3. PubMed ID: 23087513
[TBL] [Abstract][Full Text] [Related]
18. Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study.
Dorlo TPC; Kip AE; Younis BM; Ellis SJ; Alves F; Beijnen JH; Njenga S; Kirigi G; Hailu A; Olobo J; Musa AM; Balasegaram M; Wasunna M; Karlsson MO; Khalil EAG
J Antimicrob Chemother; 2017 Nov; 72(11):3131-3140. PubMed ID: 28961737
[TBL] [Abstract][Full Text] [Related]
19. Advanced case of PKDL due to delayed treatment: A rare case report.
Topno RK; Rabi Das VN; Kumar M; Madhukar M; Pandey K; Verma N; Agrawal K; Lal CS; Siddiqui NA; Bimal S; Das P
PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008052. PubMed ID: 32203500
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapeutics of visceral leishmaniasis: present and future developments.
Sundar S; Singh A
Parasitology; 2018 Apr; 145(4):481-489. PubMed ID: 29215329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
